12:00 AM
 | 
Mar 18, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Afirma Gene Expression Classifier regulatory update

Private health insurer UnitedHealthcare issued a positive medical coverage policy for Veracyte's Afirma Gene Expression Classifier for use in assessing thyroid nodule fine needle aspirate (FNA) biopsies that are indeterminate. The new medical coverage policy will apply...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >